EA202192753A1 - Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме - Google Patents
Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазмеInfo
- Publication number
- EA202192753A1 EA202192753A1 EA202192753A EA202192753A EA202192753A1 EA 202192753 A1 EA202192753 A1 EA 202192753A1 EA 202192753 A EA202192753 A EA 202192753A EA 202192753 A EA202192753 A EA 202192753A EA 202192753 A1 EA202192753 A1 EA 202192753A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amorphous solid
- plasma concentrations
- increased efficiency
- achieve therapeutic
- therapeutic plasma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Изобретение относится к твердым аморфным дисперсиям, содержащим соединение (I), имеющее формулуи один или несколько полимеров, или к составам в виде раствора, содержащим соединение (I) и один или несколько сорастворителей и поверхностно-активных веществ. Составы проявляют улучшенную стабильность и биодоступность.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962832606P | 2019-04-11 | 2019-04-11 | |
PCT/US2020/027677 WO2020210629A1 (en) | 2019-04-11 | 2020-04-10 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202192753A1 true EA202192753A1 (ru) | 2022-01-11 |
Family
ID=70465560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202192753A EA202192753A1 (ru) | 2019-04-11 | 2020-04-10 | Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220144835A1 (ru) |
EP (1) | EP3953355A1 (ru) |
JP (1) | JP2022526656A (ru) |
KR (1) | KR20210151183A (ru) |
CN (1) | CN113924300A (ru) |
AR (1) | AR118650A1 (ru) |
AU (1) | AU2020271103A1 (ru) |
BR (1) | BR112021020257A2 (ru) |
CA (1) | CA3132530A1 (ru) |
CL (1) | CL2021002627A1 (ru) |
CO (1) | CO2021015054A2 (ru) |
EA (1) | EA202192753A1 (ru) |
IL (1) | IL287103A (ru) |
MX (1) | MX2021012288A (ru) |
PE (1) | PE20212367A1 (ru) |
SG (1) | SG11202111131VA (ru) |
TW (1) | TW202104228A (ru) |
WO (1) | WO2020210629A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20230431A (es) | 2021-03-09 | 2023-10-27 | Bayer Ag | Formas de dosificación farmacéuticas que comprenden (4S)–24–cloro–4–etil–73–fluoro–35– metoxi–32,5–dioxo–14–(trifluorometil)–32H–6–aza–3(4,1)–piridina–1(1)–[1,2,3]triazola– 2(1,2),7(1) dibencenaheptafano–74–carboxamida |
AU2022345862A1 (en) | 2021-09-17 | 2024-03-14 | Bristol-Myers Squibb Company | Milvexian for prevention and treatment of thromboembolic disorders |
WO2024030409A1 (en) | 2022-08-01 | 2024-02-08 | Bristol-Myers Squibb Company | Use of milvexian for treating or preventing ischemic stroke |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI864812A (fi) | 1985-11-27 | 1987-05-28 | Syntex Inc | Foerfarande foer framstaellning av amorfa bensimidazolderivat. |
PT901786E (pt) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
WO2010102245A1 (en) | 2009-03-05 | 2010-09-10 | Upsher-Smith Laboratories, Inc. | Solid dispersion comprising resveratrol |
MX2016009230A (es) * | 2014-01-31 | 2016-10-03 | Bristol Myers Squibb Co | Macrociclicos con grupos p2'heterociclicos como inhibidores del factor xia. |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
NO2721243T3 (ru) * | 2014-10-01 | 2018-10-20 |
-
2020
- 2020-04-10 CN CN202080041944.7A patent/CN113924300A/zh active Pending
- 2020-04-10 EP EP20722195.3A patent/EP3953355A1/en active Pending
- 2020-04-10 JP JP2021559853A patent/JP2022526656A/ja active Pending
- 2020-04-10 EA EA202192753A patent/EA202192753A1/ru unknown
- 2020-04-10 KR KR1020217036797A patent/KR20210151183A/ko active Search and Examination
- 2020-04-10 MX MX2021012288A patent/MX2021012288A/es unknown
- 2020-04-10 TW TW109112257A patent/TW202104228A/zh unknown
- 2020-04-10 WO PCT/US2020/027677 patent/WO2020210629A1/en unknown
- 2020-04-10 PE PE2021001691A patent/PE20212367A1/es unknown
- 2020-04-10 US US17/602,025 patent/US20220144835A1/en active Pending
- 2020-04-10 AU AU2020271103A patent/AU2020271103A1/en active Pending
- 2020-04-10 SG SG11202111131VA patent/SG11202111131VA/en unknown
- 2020-04-10 BR BR112021020257A patent/BR112021020257A2/pt unknown
- 2020-04-10 CA CA3132530A patent/CA3132530A1/en active Pending
- 2020-04-13 AR ARP200101025A patent/AR118650A1/es unknown
-
2021
- 2021-10-07 CL CL2021002627A patent/CL2021002627A1/es unknown
- 2021-10-07 IL IL287103A patent/IL287103A/en unknown
- 2021-11-08 CO CONC2021/0015054A patent/CO2021015054A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20212367A1 (es) | 2021-12-21 |
KR20210151183A (ko) | 2021-12-13 |
MX2021012288A (es) | 2021-11-12 |
US20220144835A1 (en) | 2022-05-12 |
JP2022526656A (ja) | 2022-05-25 |
IL287103A (en) | 2021-12-01 |
SG11202111131VA (en) | 2021-11-29 |
TW202104228A (zh) | 2021-02-01 |
AR118650A1 (es) | 2021-10-20 |
EP3953355A1 (en) | 2022-02-16 |
CL2021002627A1 (es) | 2022-05-06 |
CA3132530A1 (en) | 2020-10-15 |
AU2020271103A1 (en) | 2021-12-02 |
BR112021020257A2 (pt) | 2021-12-07 |
WO2020210629A1 (en) | 2020-10-15 |
CN113924300A (zh) | 2022-01-11 |
CO2021015054A2 (es) | 2021-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202192753A1 (ru) | Повышенная эффективность аморфных твердых и солюбилизированных составов для достижения терапевтических концентраций в плазме | |
EA201791011A1 (ru) | 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ | |
EA201891103A1 (ru) | Композиции для лечения спинальной мышечной атрофии | |
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
EA201992601A1 (ru) | Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak | |
EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
EA201691261A1 (ru) | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b | |
EA201391720A1 (ru) | Замещенные диоксопиперидинилфталимидные производные | |
EA202090530A1 (ru) | Производные 1-бензил-2-имино-4-фенил-5-оксоимидазолидина как ингибиторы протеазы вич | |
EA201500653A1 (ru) | Композиции, содержащие триазольное соединение | |
EA201991349A1 (ru) | Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
EA201990279A1 (ru) | Гербицидные композиции, содержащие фенилпиримидины | |
EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
EA202190960A1 (ru) | Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30) | |
MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
EA201791896A1 (ru) | Дезацетокситубулизин н и его аналоги | |
EA201000277A1 (ru) | Соединения для лечения гепатита с | |
EA201991700A1 (ru) | Селективные ингибиторы jak1 | |
PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
EA201892815A1 (ru) | Новые антибактериальные соединения | |
EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
EA201391018A1 (ru) | Препараты иммуносупрессантов | |
EA201791667A1 (ru) | Соединения бензоксаборола и их применение | |
EA201890906A1 (ru) | ПРОИЗВОДНЫЕ ХИНОКСАЛИНА И ПИРИДОПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ |